Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Vesa Kataja et al.|Annals of Oncology|2014Cited by 1.3k
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Emiel J. Rutgers, Laura van ‘t Veer et al.|The Lancet Oncology|2021Cited by 355
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Amylou C. Dueck et al.|The Lancet Oncology|2021Cited by 255
Principles Governing A-to-I RNA Editing in the Breast Cancer TranscriptomeDebora Fumagalli, Vincent Detours, David Gacquer et al.|Cell Reports|2015Cited by 249